Mark Purcell
Stock Analyst at Morgan Stanley
(1.03)
# 3,717
Out of 4,911 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $117.70 | -3.14% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $50.37 | +9.19% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $37.97 | +15.88% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $72.66 | +16.98% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $71.70 | +67.36% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $117.70
Upside: -3.14%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $50.37
Upside: +9.19%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $37.97
Upside: +15.88%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $72.66
Upside: +16.98%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $71.70
Upside: +67.36%